Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | AKT1 | P31749 | 7/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.31 |
| ▸ | MTOR | P42345 | 3/20 | 0.31 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.30 |
| ▸ | BCL6 | P41182 | 1/20 | 0.30 |
| ▸ | DPP4 | P27487 | 1/20 | 0.30 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20916676 | 0.92 | AKT1 (0.37) | MAPTAKT1PIK3CAMTORRPS6KB1 | |
| SCHEMBL20916692 | 0.91 | BTK (0.32) | MAPT | |
| SCHEMBL20916498 | 0.86 | AKT1 (0.37) | MAPTAKT1RPS6KB1 | |
| SCHEMBL20916546 | 0.85 | AKT1 (0.30) | AKT1PIK3CAMTOR | |
| SCHEMBL20916678 | 0.85 | PIK3CD (0.37) | — | |
| SCHEMBL20916590 | 0.85 | BCL6 (0.31) | MAPTBCL6 | |
| SCHEMBL20916603 | 0.84 | PIK3CA (0.33) | PIK3CAMTORBCL6 | |
| SCHEMBL20916581 | 0.81 | BTK (0.36) | MAPTAKT1RPS6KB1 | |
| SCHEMBL20916699 | 0.78 | PIK3CD (0.33) | — | |
| SCHEMBL20916638 | 0.77 | PIK3CD (0.34) | AKT1RPS6KB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3697777-A1 | BENZIMIDAZOLE-INDOLE INHIBITORS OF MNK1 AND MNK2 | eFFECTOR Therapeutics, Inc. (US) | 2020-08-26 | — | — | EP | claimed |
| WO-2019079369-A1 | BENZIMIDAZOLE-INDOLE INHIBITORS OF MNK1 AND MNK2 | EFFECTOR THERAPEUTICS, INC. (US) | 2019-04-25 | — | — | WO | claimed |
| US-20190119256-A1 | BENZIMIDAZOLE-INDOLE INHIBITORS OF MNK1 AND MNK2 | EFFECTOR THERAPEUTICS, INC. (JP) | 2019-04-25 | — | — | US | claimed |
| US-10793551-B2 | Benzimidazole-indole inhibitors of Mnk1 and Mnk2 | Effector Therapeutics Inc. (US) | 2020-10-06 | — | — | US | disclosed |
| EP-3697777-A1 | BENZIMIDAZOLE-INDOLE INHIBITORS OF MNK1 AND MNK2 | eFFECTOR Therapeutics, Inc. (US) | 2020-08-26 | — | — | EP | disclosed |
| US-20190119256-A1 | BENZIMIDAZOLE-INDOLE INHIBITORS OF MNK1 AND MNK2 | EFFECTOR THERAPEUTICS, INC. (JP) | 2019-04-25 | — | — | US | disclosed |
| WO-2019079369-A1 | BENZIMIDAZOLE-INDOLE INHIBITORS OF MNK1 AND MNK2 | EFFECTOR THERAPEUTICS, INC. (US) | 2019-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190119256-A1 | BENZIMIDAZOLE-INDOLE INHIBITORS OF MNK1 AND MNK2 | NEK5, MINK1, NIM1K | MAPT 553/4885AKT1 883/4885PIK3CA 2719/4885 |
| US-10793551-B2 | Benzimidazole-indole inhibitors of Mnk1 and Mnk2 | NEK5, MINK1, NIM1K | MAPT 553/4885AKT1 883/4885PIK3CA 2719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.